

#27/I.D.S

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. MBM1250-2	Serial No.: 09/296,264
	Applicant(s): Jim A. Wright et al..	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: April 22, 1999	Group Art Unit: 1635

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
		None					

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
MMS	AA	WO97/21808	19.06.97	PCT			
	AB	WO99/02556	21.01.99	PCT			
	AC	WO99/04263	01.28.99	PCT			
	AD	WO94/08625	04.28.94	PCT			
	AE	WO99/29729	06.17.99	PCT			
	AF	WO97/15662	05.01.97	PCT			


RECEIVED

DEC 04 2002

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

MMS	AG	Good and Nielsen; "Inhibition of translation and bacterial growth by polypeptide nucleic acid targeted to ribosomal RNA", PNAS USA (1998) 95:2073-2076
	AH	Sullivan, S.M., "Development of ribozymes for gene therapy", J. Invest. Dermatol. 1(1994) 103(5 Suppl): 85S-89S
	AI	Agrawal, S., "Antisense oligonucleotides: towards clinical trials" Trends Biotechnol., October 1996, 14:376-387
	AJ	Branch, Andrea D., 1998. TIBS 23 pp. 45-50
	AK	Flanagan et al., 1998. Nature Biotech 17:48-52

EXAMINER 	DATE CONSIDERED 12/17/02
--	------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


RECEIVED

DEC 04 2002

TECH CENTER 1600/2900

FORM PTO-1449 U.S. Department of Commerce, Patent and Trademark Office NOV 29 2002	Docket No. MBM1250-2	Serial No.: 09/296,264
Applicant(s): Jim A. Wright et al..		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: April 22, 1999	Group Art Unit: 1635

	AL	Crystal, R.G., 1995, Science 270:404-410
Mus	AM	Crooke S.T., 1998 Antisense Research and Application: Basic Principles of Antisense Therapeutics Ch. 1 pp 1-50
	AN	Soker S. et al., 1998, Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92(92): 735-745
	AO	Curcio, L.D., Bouffard, D.Y., and Scanlon, K.J. Oligonucleotides as modulators of cancer gene expression, Pharmacol Ther. 74:317-32, 1997
	AP	Narayanan, R. and Akhtar, S. Antisense therapy, Curr. Opin Oncol. 8:509-15, 1996.
	AQ	Ho, P.T. and Parkinson, D.R., Antisense oligonucleotides as therapeutics for malignant diseases, Semin Oncol. 24:187-202, 1997.
	AR	Crooke, S.T. and Bennett, C.F. Progress in antisense oligonucleotide therapeutics, Annu Rev. Pharmacol. Toxicol. 36:107-29, 1996
	AS	Mitsuhashi, M., "Strategy for designing specific antisense oligonucleotide sequences" J. Gastroenterol. 32:282-7, 1997
	AT	Alama, A. et al., "Antisense oligonucleotides as therapeutic agents", Pharmacol. Res. 36:171-8, 1997
	AU	Brem, S. et al., "Prolonged tumor dormancy by prevention of neovascularization in the vitreous", Cancer Res. 36:2807-12, 1976
	AV	Holmgren, L. et al., "Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression", Nat. Med. 1:149-53, 1995
	AW	Parangi, S. et al., "Antiangiogenic therapy of transgenic mice impairs de novo tumor growth, Proc. Acad. Natl. Sci. USA 93:2002-2007, 1996
	AX	Uhlmann et al., Chem. Rev. 90:534-583, 1990
	AY	Agrawal, Antisense Oligonucleotides as Antiviral agents, Trends Biotechnol. 10:152-158, 1992
	AZ	Smith et al., Oxygen-Induced Retinopathy in the Mouse, 1994. Invest. Ophthalmol. Vis. Sci 35:101-111


EXAMINER 	DATE CONSIDERED 12/17/02
--	------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No. MBM1250-2	Serial No.: 09/296,264 DEC 04 2002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant(s): Jim A. Wright et al.. Filing Date: April 22, 1999	TECH CENTER 1600/2900 Group Art Unit: 1635

mas	BA	Pierce et al., Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization, 1995. Proc. Acad. Natl. Sci. USA 92:905-909
.	BB	Tischer, E. et al., "The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing", J. Biol. Chem. 266:11947-54, 1991
.	BC	Poltorak, Z., et al., "VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix", J. Biol. Chem. 272:7151-7158, 1997
.	BD	Terman, B.I., et al., "Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor", Biochem. Biophys. Res. Commun. 187:1579-86, 1992
.	BE	Millauer, B., et al. "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis", Cell. 72:835-846, 1993
.	BF	Shibuya, M., et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family", Oncogene. 5:519-524, 1990
2	BG	De Vries, C., et al., "The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor", Science. 255:989-991, 1992
.	BH	Kawakami, A., et al., "Developmentally regulated expression of a cell surface protein, neuropilin, in the mouse nervous system", J. Neurobiol. 29:1-17, 1996
.	BI	Takagi, S. et al., "Expression of a cell adhesion molecule, neuropilin, in the developing chick nervous system", Dev. Biol. 170:207-222, 1995
.	BJ	Soker, S. et al., "Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of FEGF165", J. Biol. Chem. 272:31582-8, 1997
✓	BK	He, Z. and Tessier-Lavigne, M. "Neuropilin is a receptor for the axonal chemorepellent Semaphorin III", Cell. 90:739-51, 1997

EXAMINER 	DATE CONSIDERED 12/17/02
--	------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.